We are live on ! Find out more
KLDO

Kaleido Biosciences, Inc. Common Stock
KLDO

Delisted

KLDO was delisted on the 14th of April, 2022.

Back to rankings

41 hedge funds and large institutions have $180M invested in Kaleido Biosciences, Inc. Common Stock in 2019 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 15 increasing their positions, 7 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

250% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 2

114% more repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 7

11% more funds holding

Funds holding: 37 → 41 (+4)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

34% less capital invested

Capital invested by funds: $273M → $180M (-$92.8M)

Holders
41
Holders Change
+4
Holders Change %
+10.81%
% of All Funds
0.9%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
7
Increased
15
Reduced
7
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$1.96M
2
Northern Trust
Northern Trust
Illinois
+$518K
3
BII
Bainco International Investors
Massachusetts
+$384K
4
Victory Capital Management
Victory Capital Management
Texas
+$377K
5
Fidelity Investments
Fidelity Investments
Massachusetts
+$353K

Top Sellers

Rank Fund Capital Flow
1
PAI
Palo Alto Investors
California
-$683K
2
ACPU
Arrowgrass Capital Partners (US)
Delaware
-$525K
3
Millennium Management
Millennium Management
New York
-$63.2K
4
TRCT
Tower Research Capital (TRC)
New York
-$56K
5
Deutsche Bank
Deutsche Bank
Germany
-$27.8K
Name Holding Trade Value Shares
Change 		Change in
Stake
FP
1
Flagship Pioneering
Massachusetts
$131M – – –
Fidelity Investments
2
Fidelity Investments
Massachusetts
$14.8M +$353K +40,617 +2%
HP
3
Harbourvest Partners
Massachusetts
$8.79M – – –
AG
4
Artal Group
Luxembourg
$6.78M – – –
PAI
5
Palo Alto Investors
California
$5.93M -$683K -78,667 -9%
Baillie Gifford & Co
6
Baillie Gifford & Co
United Kingdom
$3.31M – – –
Vanguard Group
7
Vanguard Group
Pennsylvania
$2.39M +$1.96M +225,359 +246%
BlackRock
8
BlackRock
New York
$1.9M +$74.3K +8,555 +4%
Victory Capital Management
9
Victory Capital Management
Texas
$1.01M +$377K +43,394 +48%
RSCM
10
Rock Springs Capital Management
Maryland
$753K – – –
State Street
11
State Street
Massachusetts
$598K +$89.4K +10,300 +15%
Geode Capital Management
12
Geode Capital Management
Massachusetts
$586K +$894 +103 +0.1%
KA
13
Kerrisdale Advisers
Florida
$546K – – –
Northern Trust
14
Northern Trust
Illinois
$543K +$518K +59,656 +478%
BII
15
Bainco International Investors
Massachusetts
$333K +$384K +44,237 New
BCM
16
Barometer Capital Management
Ontario, Canada
$226K – – –
Charles Schwab
17
Charles Schwab
California
$211K -$20.6K -2,370 -8%
Millennium Management
18
Millennium Management
New York
$161K -$63.2K -7,283 -25%
Citadel Advisors
19
Citadel Advisors
Florida
$161K +$185K +21,362 New
Bank of New York Mellon
20
Bank of New York Mellon
New York
$130K +$150K +17,246 New
First Trust Advisors
21
First Trust Advisors
Illinois
$92K +$106K +12,182 New
IWM
22
IHT Wealth Management
Illinois
$82K +$95.1K +10,950 New
Wells Fargo
23
Wells Fargo
California
$81K +$92.8K +10,695 +27,423%
New York State Common Retirement Fund
24
New York State Common Retirement Fund
New York
$67K – – –
California State Teachers Retirement System (CalSTRS)
25
California State Teachers Retirement System (CalSTRS)
California
$58K – – –
1
2

KLDO Hedge Fund Activity: Q3 2019 in Review

41 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Kaleido Biosciences, Inc. Common Stock (KLDO) for Q3 2019, worth a combined $180M — down 34% from $273M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new KLDO positions and 2 closed out — a net gain of 5 holders — while 15 added to existing stakes and 7 trimmed.

The largest buyer was Vanguard Group, adding an estimated $1.96M. The largest seller was Palo Alto Investors, cutting an estimated $683K.

  • 41 institutional investors held Kaleido Biosciences, Inc. Common Stock (KLDO) as of Q3 2019, up from 37 in Q2 2019.
  • Funds reported $180M of Kaleido Biosciences, Inc. Common Stock stock for Q3 2019, down 34% quarter-over-quarter.
  • 7 funds opened new Kaleido Biosciences, Inc. Common Stock positions in Q3 2019 and 2 closed out, a net change of +5 holders.
  • The largest Kaleido Biosciences, Inc. Common Stock buyer in Q3 2019 was Vanguard Group, an estimated $1.96M added.
  • The largest Kaleido Biosciences, Inc. Common Stock seller in Q3 2019 was Palo Alto Investors, an estimated $683K sold.

Based on aggregated 13F filings for Q3 2019.